Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry

References

• Bonhorst D, Mendes M, de Sousa J et al. [Epidemiology of atrial fibrillation]. Rev. Port. Cardiol.29(7–8), 1207–1217 (2010).
   PubMedGoogle Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114(7), e257–e354 (2006).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol. Clin.27(1), 13–24 (2009).
   PubMedGoogle Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol.82(8A), 2N–9N (1998).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation110(9), 1042–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin. Cardiol.31(2), 55–62 (2008).
   PubMed Web of Science ®Google Scholar
• Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am. J. Cardiol.74(3), 236–241 (1994).
   PubMed Web of Science ®Google Scholar
• Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J.27(8), 949–953 (2006).
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347(23), 1825–1833 (2002).
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med.347(23), 1834–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Crijns HJ, Tieleman RG et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch. Intern. Med.156(22), 2585–2592 (1996).
   PubMedGoogle Scholar
• Blackshear JL, Safford RE. AFFIRM and RACE trials: implications for the management of atrial fibrillation. Card. Electrophysiol. Rev.7(4), 366–369 (2003).
   PubMedGoogle Scholar
• Groenveld HF, Crijns HJ, Rienstra M, Van den Berg MP, Van Veldhuisen DJ, Van Gelder IC. Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. Am. Heart J.158(5), 785–791 (2009).
   PubMed Web of Science ®Google Scholar
• Groenveld HF, Crijns HJ, Van den Berg MP et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J. Am. Coll. Cardiol.58(17), 1795–1803 (2011).
   PubMedGoogle Scholar
• Van Gelder IC, Groenveld HF, Crijns HJ et al. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med.362(15), 1363–1373 (2010).
   PubMed Web of Science ®Google Scholar
• Bijsterveld N. [No improvement in prognosis by intensive rate control in atrial fibrillation]. Ned Tijdschr Geneeskd.154(9), 425 (2010).
   Google Scholar
• Roy D, Talajic M, Nattel S et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med.358(25), 2667–2677 (2008).
   PubMed Web of Science ®Google Scholar
• Caldeira D, David C, Sampaio C. Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials. Eur. J. Intern. Med.22(5), 448–455 (2011).
   PubMed Web of Science ®Google Scholar
• Kumana CR, Cheung BM, Cheung GT, Ovedal T, Pederson B, Lauder IJ. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br. J. Clin. Pharmacol.60(4), 347–354 (2005).
   PubMedGoogle Scholar
• Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. Eur. Heart J.26(19), 2000–2006 (2005).
   PubMed Web of Science ®Google Scholar
• Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med. Clin. North Am.92(1), 17–40 (2003).
   Google Scholar
• Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb. Res.118(3), 321–333 (2006).
   PubMed Web of Science ®Google Scholar
• Steg PG, Alam S, Chiang CE et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the REALISE-AF cross-sectional international registry. Heart98(3), 195–201 (2012).
   PubMedGoogle Scholar
• Kirchhof P, Auricchio A, Bax J et al. Outcome parameters for trials in atrial fibrillation: executive summary. Eur. Heart J.28(22), 2803–2817 (2007).
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur. Heart J.26(22), 2422–2434 (2005).
   PubMed Web of Science ®Google Scholar
• Singh SN, Tang XC, Singh BN et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a veterans affairs cooperative studies program substudy. J. Am. Coll. Cardiol.48(4), 721–730 (2006).
   PubMed Web of Science ®Google Scholar
• Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur. Heart J.24(15), 1430–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet356(9244), 1789–1794 (2000).
   PubMed Web of Science ®Google Scholar
• Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol.41(10), 1690–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Opolski G, Torbicki A, Kosior DA et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest126(2), 476–486 (2004).
   PubMed Web of Science ®Google Scholar
• Cordina J, Mead G. Pharmacological cardioversion for atrial fibrillation and flutter. Cochrane Database Syst. Rev.2, CD003713 (2005).
   Google Scholar
• Okcun B, Yigit Z, Arat A, Kucukoglu SM. Comparison of rate and rhythm control in patients with atrial fibrillation and nonischemic heart failure. Jpn Heart J.45(4), 591–601 (2004).
   PubMedGoogle Scholar
• Singer DE. Anticoagulation to prevent stroke in atrial fibrillation and its implications for managed care. Am. J. Cardiol.81(5A), 35C–40C (1998).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA285(22), 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet343(8899), 687–691 (1994).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med.360(20), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet367(9526), 1903–1912 (2006).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation123(1), 104–123 (2011).
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol.21(6), 597–605 (2010).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Lassen MR, Davidson BL et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet373(9676), 1673–1680 (2009).
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Brenner B, Dahl OE et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet372(9632), 31–39 (2008).
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, Phase II trial. Lancet374(9683), 29–38 (2009).
   PubMed Web of Science ®Google Scholar
• ROCKET-AF Study Investigators. Rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J.159(3), 340–347, e341 (2010).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med.365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander JH, Al-Khatib SM et al. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J.159(3), 331–339 (2010).
   PubMed Web of Science ®Google Scholar
• Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet374(9689), 534–542 (2009).
   PubMed Web of Science ®Google Scholar